Optimizing the Implementation of Tobacco Treatment for People with HIV: A Pilot Study

Int J Environ Res Public Health. 2022 Oct 8;19(19):12896. doi: 10.3390/ijerph191912896.

Abstract

People with HIV (PWH) have higher rates of tobacco use compared to their societal counterparts and are disproportionately affected by tobacco-related morbidity and mortality. A needs assessment was conducted to assess provider beliefs and opinions on tobacco treatment barriers and treatment approaches. The results highlighted a disconnect between the known importance of quitting smoking and barriers in linking patients to treatment, such as lack of patient interest and other patient issues being a higher priority. Using this assessment data, a treatment delivery approach, Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement (PrOMOTE), was devised and piloted. PrOMOTE consisted of an outpatient clinical pharmacist trained in tobacco treatment proactively contacting patients for counseling and to prescribe smoking cessation pharmacotherapy (varenicline or dual nicotine replacement therapy (NRT)) using an opt-out approach. The pilot was conducted with 10 PWH and patient reach and opt-out rates were evaluated. Of the 10 patients contacted, 7 were reached and none opted out of the pharmacotherapy prescription (varenicline = 6; NRT = 1). Providers know the importance of smoking cessation for PWH but encounter several barriers to implementing treatment. Using PrOMOTE methods to deliver tobacco treatment increased the reach and pharmacotherapy acceptance rate of PWH who smoke.

Keywords: HIV/AIDS; implementation; smoking cessation; tobacco treatment.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • HIV Infections* / drug therapy
  • Humans
  • Nicotiana
  • Nicotinic Agonists / therapeutic use
  • Pilot Projects
  • Smoking Cessation* / methods
  • Tobacco Use
  • Tobacco Use Cessation Devices
  • Varenicline / therapeutic use

Substances

  • Nicotinic Agonists
  • Varenicline